Triangle Securities Wealth Management Has $2.71 Million Holdings in Johnson & Johnson $JNJ

Key Points

• Triangle Securities Wealth Management reduced its stake in Johnson & Johnson (NYSE:JNJ) by 10.7% in the 2nd quarter, holding 17,749 shares worth approximately $2.71 million after selling 2,116 shares.
• Several institutional investors increased their holdings in JNJ, with Brighton Jones LLC's stake rising by 13.9%, now owning 51,876 shares worth $7.5 million.
• Johnson & Johnson's most recent earnings report showed an EPS of $2.77, surpassing analysts' expectations, and the company announced a quarterly dividend of $1.30 per share with a yield of 3.0%.

Triangle Securities Wealth Management reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,749 shares of the company's stock after selling 2,116 shares during the period. Triangle Securities Wealth Management's holdings in Johnson & Johnson were worth $2,711,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of JNJ. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares in the last quarter. Hudson Value Partners LLC lifted its holdings in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $9,222,000. 49 Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at $211,000. Finally, Retirement Planning Group LLC increased its position in Johnson & Johnson by 11.4% in the 4th quarter. Retirement Planning Group LLC now owns 5,677 shares of the company's stock worth $821,000 after purchasing an additional 580 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on JNJ. Morgan Stanley raised their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Citigroup increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday, August 21st. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Finally, JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research note on Tuesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $181.40.

Johnson & Johnson Price Performance

JNJ traded up $2.56 on Tuesday, reaching $176.77. 1,645,416 shares of the company's stock were exchanged, compared to its average volume of 8,906,436. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock's fifty day moving average price is $173.14 and its 200-day moving average price is $161.69. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The stock has a market cap of $425.72 billion, a PE ratio of 18.88, a P/E/G ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.